Regeneron Pharmaceuticals, INC.: insider trades · United States · SEC (Form 4)

About Regeneron Pharmaceuticals, INC.

Regeneron Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker REGN. Headquartered in Tarrytown, New York, in the United States, the company was founded in 1988 and has built a reputation as one of the most scientifically driven large-cap biotechnology companies. Its business model is highly integrated, spanning discovery, development, and commercialization, with a strong internal research culture and proprietary platforms such as VelociSuite® and the Regeneron Genetics Center®. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)) Regeneron develops and commercializes medicines across several therapeutic areas, including eye diseases, allergic and inflammatory disorders, oncology, cardiovascular and metabolic diseases, rare diseases, infectious diseases, and selected neurological conditions. Its best-known products include Dupixent® (co-marketed with Sanofi), EYLEA® and EYLEA HD® for retinal diseases, Libtayo® in oncology, and additional products such as Praluent®, Kevzara®, Evkeeza®, Inmazeb®, and Veopoz®. Despite this broader portfolio, the company’s earnings profile remains anchored by a few major franchises, especially Dupixent and the EYLEA/EYLEA HD ophthalmology franchise, which are central to its growth and profitability profile. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)) From a competitive standpoint, Regeneron is widely regarded as a leading biotech because of its ability to convert scientific discovery into approved medicines at scale. The company stands out for its expertise in antibody engineering, protein biology, and genetic medicine, allowing it to maintain a deep pipeline with many programs originating in-house. In 2025 and early 2026, Regeneron continued to expand both its commercial portfolio and clinical pipeline, with regulatory approvals and late-stage progress across immunology, ophthalmology, oncology, and rare diseases. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)) Recent highlights include the FDA’s April 2026 approval of EYLEA HD with dosing intervals of up to 20 weeks in certain retinal indications, multiple new Dupixent approvals in 2025-2026, and the accelerated approval of Otarmeni™, Regeneron’s first genetic medicine and first gene therapy in a rare hearing-loss indication. The company also announced a radiopharmaceutical collaboration with Telix and a U.S. government agreement related to pricing for certain medicines, while reiterating its commitment to substantial domestic R&D and manufacturing investment. For international investors, Regeneron remains a high-quality growth name in Health & Pharma, combining a proprietary science platform, a deep pipeline, and leading commercial franchises on the U.S. NASDAQ market. ([investor.regeneron.com](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-approved-fda-first-and-only-injectable/?utm_source=openai))